Company profile for Gylden Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gylden is a clinical-stage, privately held biotechnology company based in Abingdon, Oxfordshire, UK. It operates R&D and GMP manufacturing facilities in Milton Park, Oxfordshire, along with a subsidiary in Doylestown, Pennsylvania, USA, and a manufacturing site in Fremont, California, USA. The company is at the forefront of developing synthetic T cell-priming vaccines and immunotherapies that replicate the body’s natural cel...
Gylden is a clinical-stage, privately held biotechnology company based in Abingdon, Oxfordshire, UK. It operates R&D and GMP manufacturing facilities in Milton Park, Oxfordshire, along with a subsidiary in Doylestown, Pennsylvania, USA, and a manufacturing site in Fremont, California, USA. The company is at the forefront of developing synthetic T cell-priming vaccines and immunotherapies that replicate the body’s natural cellular immune response to eliminate pathogen-infected cells, addressing some of the world’s most pressing health challenges.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
4/5 Dunmore Court Wootton Road Abingdon OX13 6BH
Telephone
Telephone
+44 (0) 1235 527589
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/02/24/3031017/0/en/Gylden-s-2025-Strategic-Priorities-for-Advancing-Innovative-and-Transformative-Solutions-for-Infectious-Diseases.html

GLOBENEWSWIRE
24 Feb 2025

https://www.globenewswire.com/news-release/2024/10/17/2965052/0/en/Emergex-Announces-Company-Name-Change-to-Gylden-Pharma-Limited-Reflecting-Company-s-Commitment-to-Advanced-Core-Technologies-and-Expanded-Product-Pipeline.html

GLOBENEWSWIRE
17 Oct 2024

https://www.globenewswire.com//en/news-release/2024/10/02/2956817/0/en/Emergex-T-Cell-Priming-Vaccine-Candidate-for-Betacoronaviruses-selected-by-NIH-NIAID-Project-NextGen-for-Inclusion-in-Clinical-Trials.html

GLOBENEWSWIRE
02 Oct 2024

https://www.globenewswire.com/news-release/2024/08/22/2934121/0/en/Emergex-Receives-Patent-Protection-for-First-in-Class-Influenza-A-Vaccines-with-Potential-to-Provide-Long-Term-T-Cell-Immunity.html

GLOBENEWSWIRE
22 Aug 2024

https://www.globenewswire.com/news-release/2024/06/18/2900273/0/en/Emergex-Announces-MHRA-Approval-of-MIA-IMP-Manufacturing-and-Import-Authorisation-License.html

GLOBENEWSWIRE
18 Jun 2024

https://www.globenewswire.com//news-release/2024/01/16/2809755/0/en/Emergex-Announces-R-D-Collaboration-with-DEKA-Research-Development-Corp-for-Assessment-of-Emergex-s-Immunotherapeutic-Candidates-with-DEKA-s-Intradermal-Therapeutic-Applicator.html

GLOBENEWSWIRE
16 Jan 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty